Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Parkinson disease

Laying the foundations for disease-modifying therapies in PD

Nature Reviews Neurology volume 11, pages 553–555 (2015)Cite this article

Subjects

The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14, 795–803 (2015).

  2. Carta, A. R. PPAR-γ: therapeutic prospects in Parkinson's disease. Curr. Drug Targets 14, 743–751 (2013).

    Article  CAS  Google Scholar 

  3. Levin, D. et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493–504 (2015).

    Article  CAS  Google Scholar 

  4. Petit, G. H., Olsson, T. T. & Brundin, P. The future of cell therapies and brain repair: Parkinson's disease leads the way. Neuropathol. Appl. Neurobiol. 40, 60–70 (2014).

    Article  CAS  Google Scholar 

  5. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29, 454–462 (2014).

    Article  Google Scholar 

  6. Santiago, J. A. & Potashkin, J. A. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176–186 (2013).

    Article  CAS  Google Scholar 

  7. Brauer, R. et al. Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med. 12, e1001854 (2015).

    Article  Google Scholar 

  8. Aviles-Olmos, I. et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337–344 (2014).

    Article  CAS  Google Scholar 

  9. US National Library of Medicine. ClinicalTrials.gov[online], (2015).

  10. Brundin, P. et al. Linked clinical trials—the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. J. Parkinsons Dis. 3, 231–239 (2013).

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Van Andel Research Institute, Translational Parkinson's Disease Research, Center for Neurodegenerative Science, 333 Bostwick Avenue NE, Grand Rapids, 49503, MI, USA

    Patrik Brundin

  2. The Cure Parkinson's Trust, 120 Baker Street, London, W1U 6TU, UK

    Richard Wyse

Authors
  1. Patrik Brundin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Wyse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrik Brundin.

Ethics declarations

Competing interests

P.B. has received commercial support from Capital Technologies, Renovo Neural, Roche, Teva, Lundbeck, ClearView Healthcare Partners, FCB Health and IOS Press, and research support from Renovo Neural, Teva and Lundbeck. He has ownership interests in AcouSort and ParkCell. R.W declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brundin, P., Wyse, R. Laying the foundations for disease-modifying therapies in PD. Nat Rev Neurol 11, 553–555 (2015). https://doi.org/10.1038/nrneurol.2015.150

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.150

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing